KINIKSA PHARMACEUTICALS, LTD.

Analyst Reco. Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
19.06 ^USD	-2.36%		+0.26%	+8.67%

May. 14	Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM
Apr. 23	Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Adjusts Kiniksa Pharmaceuticals' PT to $30 From $28, Maintains Outperform Rating	Apr. 03	MT
Wedbush Lifts Kiniksa Pharmaceuticals' PT to $25 From $23 Ahead of Planned Q1 Reporting of Initial Data on KPL-404; Maintains Outperform Rating	Jan. 02	MT
Wedbush Adjusts Kiniksa Pharmaceuticals Price Target to $23 From $21, Maintains Outperform Rating	23-07-25	MT
Wedbush Raises Kiniksa Pharmaceuticals Price Target to $21 From $20, Maintains Outperform Rating	23-05-02	MT
JPMorgan Adjusts Kiniksa Pharmaceuticals' Price Target to $20 From $19, Keeps Overweight Rating	23-03-09	MT
Wedbush Lowers Kiniksa Pharmaceuticals' Price Target to $20 From $26, Adjusts Commercial Ramp Assumptions for Arcalyst; Keeps Outperform Rating	23-03-01	MT
Wedbush Lifts Price Target on Kiniksa Pharmaceuticals to $26 From $25, Keeps Outperform Rating	22-11-02	MT
Wedbush Lifts Price Target for Kiniksa Pharmaceuticals to $25 From $24, Maintains Outperform Rating	22-05-03	MT
Wedbush Lowers Price Target for Kiniksa Pharmaceuticals to $24 From $28, Maintains Outperform Rating	22-02-22	MT
Wedbush Lifts Price Target on Kiniksa Pharmaceuticals to $28 From $25.91; Outperform Rating Kept	22-01-11	MT
BofA Securities Adjusts Kiniksa Pharmaceuticals' Price Target to $34 From $37, Reiterates Buy Rating	21-12-29	MT
JPMorgan Adjusts Price Target on Kiniksa Pharmaceuticals to $27 From $30, Reiterates Overweight Rating	21-11-02	MT
Wedbush Lifts Kiniksa Pharmaceuticals' Price Target to $26 From $24; Outperform Rating Kept	21-11-02	MT
KINIKSA PHARMACEUTICALS : Wedbush Cuts Price Target on Kiniksa Pharmaceuticals to $24 From $32, Citing Vixarelimab Launch Timeline; Outperform Rating Kept	21-08-04	MT
KINIKSA PHARMACEUTICALS : Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $32 From $35 on Estimated Mavrilimumab Launch Date; Outperform Rating Kept	21-06-09	MT
KINIKSA PHARMACEUTICALS : Evercore ISI Starts Kiniksa Pharmaceuticals at Outperform with $25 Price Target	20-11-24	MT
KINIKSA PHARMACEUTICALS : Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $35 From $38, Keeps Outperform Rating	20-11-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer